Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers

Dr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers.